Skip to main
GOSS

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 50%
Hold 17%
Sell 17%
Strong Sell 0%

Bulls say

Gossamer Bio is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapeutics in the areas of immunology, inflammation, and oncology. Its positive outlook is based on a strong regulatory strategy and a fully funded path to approval and launch in 2027, supported by a strong management team with a plan for a potential September 2026 NDA submission. However, the company's liquidity remains constrained despite a recent exchange offer, and its success will depend on constructive feedback from the FDA on its NDA and the removal of its significant near-term maturity wall.

Bears say

Gossamer Bio is facing several challenges that could hinder its success in the clinical-stage biopharmaceutical industry, including a high-risk niche focus that may limit its commercial opportunity, potential anti-fibrotic activity that has not yet been fully validated, and a cost-cutting measure that may impact the company's ability to advance its pipeline products. Additionally, while the company's data may provide biological coherence and strengthen its pharmacodynamic narrative, it does not fully de-risk its potential opportunities without clinical data. Furthermore, although management has indicated that the upcoming FDA meeting may be pivotal for the company, there is still uncertainty around the site exclusion issue and the potential impact it may have on the company's data.

GOSS has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Buy based on their latest research and market trends.

According to 6 analysts, GOSS has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.